Extracorporeal photopheresis for the treatment of autoimmune diseases

Adamski, Jill; Kinard, Theresa N.; Ipe, Tina S.; Cooling, Laura

doi:10.1016/j.transci.2015.02.005

Cited by 28 publications

(26 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, ECP induces a significant increase in circulating CD4 + CD25 + Treg cells, associated with a tolerogenic phenotype that is present for up to one year following treatment 11,16,17,21. Lastly, ECP preserves host responses to foreign antigens, avoiding the increased risk of infection due to immunosuppression 4,6,11,15,17,22,23…”

Section: Discussionmentioning

confidence: 99%

Novel Application of Extracorporeal Photopheresis as Treatment of Graft-versus-Host Disease Following Liver Transplantation

Brown

Gentry

Hammer

et al. 2017

ACG Case Reports Journal

View full text Add to dashboard Cite

A 48-year-old man with hepatitis C virus (HCV) cirrhosis complicated by hepatocellular carcinoma underwent liver transplantation. His course was complicated by fever, diarrhea, abdominal pain, and pancytopenia. He developed a diffuse erythematous rash, which progressed to erythroderma. Biopsies of the colon and skin were consistent with acute graft-versus-host disease. Donor-derived lymphocytes were present in the peripheral blood. The patient was treated with corticosteroids and cyclosporine; however, he had minimal response to intensive immunosuppressive therapy. Extracorporeal photopheresis was initiated as a salvage therapy. He had a dramatic response, and his rash, diarrhea, and pancytopenia resolved. He is maintained on minimal immunosuppression 24 months later.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel Application of Extracorporeal Photopheresis as Treatment of Graft-versus-Host Disease Following Liver Transplantation

Brown

Gentry

Hammer

et al. 2017

ACG Case Reports Journal

View full text Add to dashboard Cite

show abstract

“…Therapeutic apheresis was utilized to avoid the side effects of topical and immunosuppressive agents. Use of ECP has been well studied in AD . Most articles on ECP therapy of AD reported a regimen of 2 consecutive treatments every 2 weeks for 12 weeks, followed by regimented tapering off .…”

Section: New Diseases – Category IIImentioning

confidence: 99%

Critical updates in the 7^th edition of the American Society for Apheresis guidelines

Ipe

Pham

Williams

2017

J of Clinical Apheresis

View full text Add to dashboard Cite

The 7 th edition of the American Society for Apheresis (ASFA) guidelines was composed by an international physicians committee, and includes 14 new diseases, and 2 new indications for diseases described in the former guidelines. Several indications have either changed names or were excluded from this edition. The guidelines are developed after taking into account documented evidence, either supporting or negating use of apheresis technology in the treatment of diseases. Based on this evidence, the committee revises, updates and includes or excludes disease entities/indications in the guidelines. This article describes the revisions to the 7 th edition of the ASFA guidelines, in a comprehensive manner. K E Y W O R D Sapheresis, ASFA guidelines, critical updates, diseases and indications, 7th edition

show abstract

“…Extracorporeal photopheresis (ECP) is an autologous cell therapy in which leukocytes collected by cytapheresis are incubated with 8 methoxy‐psoralen (8‐MOP), irradiated with UVA, before reinfusion to the patient. ECP is used to treat diseases with circulating pathogenic T cells, such as cutaneous T cell lymphoma (CTCL), graft vs host disease (GVHD), and various T‐cell mediated disorders (organ transplant rejection, auto‐immune or inflammatory diseases). Despite its widespread use, ECP mechanisms of action have long been a matter of debate .…”

Section: Introductionmentioning

confidence: 99%

In vitro PUVA treatment triggers calreticulin exposition and HMGB1 release by dying T lymphocytes in GVHD: New insights in extracorporeal photopheresis

Coppard

Hannani

Humbert

et al. 2019

J of Clinical Apheresis

View full text Add to dashboard Cite

Background Extracorporeal photopheresis (ECP) is an effective therapy for graft vs host disease (GVHD), based on infusion of UVA‐irradiated and 8 methoxy‐psoralen (PUVA)‐treated leukocytes. Reinfusion of these apoptosing cells affects the functionality of pathogenic T cells through poorly understood immunomodulatory mechanisms. Apoptosis is usually a silent, tolerance‐associated process, but can also be immunogenic, depending on death‐inducers and environmental context. Methods To understand ECP mechanisms of action, human alloreactive T cells generated in an in vitro model mimicking GVHD were used, as well as primary cells from GVHD patients. Cells were submitted to PUVA treatment and their phenotype and immunogenicity were analyzed, using cell culture and flow cytometry. Results In vitro PUVA treatment induced the expression of several damage‐associated molecular patterns (DAMPs) by dying T cells (calreticulin, high‐mobility group box‐1, and to a lesser extent heat shock proteins 70 and 90), especially upon T cell activation, leading to their phagocytosis by macrophages and dendritic cells (DCs). Allogeneic DCs preincubated with PUVA treated T cells induced comparable naive T cell proliferation and polarization as control allogeneic DC. Conclusion Altogether, in our experimental settings, in vitro PUVA‐treatment induces a partially immunogenic phenotype allowing phagocytosis of apoptotic cells by macrophages and DC, however not sufficient to induce dendritic cell maturation and T cell activation. These data refine current models of ECP‐mediated immune modulation and emphasize the need to further analyze PUVA‐treated cell interactions with immune cells.

show abstract

Extracorporeal photopheresis for the treatment of autoimmune diseases

Cited by 28 publications

References 96 publications

Novel Application of Extracorporeal Photopheresis as Treatment of Graft-versus-Host Disease Following Liver Transplantation

Novel Application of Extracorporeal Photopheresis as Treatment of Graft-versus-Host Disease Following Liver Transplantation

Critical updates in the 7^th edition of the American Society for Apheresis guidelines

In vitro PUVA treatment triggers calreticulin exposition and HMGB1 release by dying T lymphocytes in GVHD: New insights in extracorporeal photopheresis

Contact Info

Product

Resources

About

Extracorporeal photopheresis for the treatment of autoimmune diseases

Cited by 28 publications

References 96 publications

Novel Application of Extracorporeal Photopheresis as Treatment of Graft-versus-Host Disease Following Liver Transplantation

Novel Application of Extracorporeal Photopheresis as Treatment of Graft-versus-Host Disease Following Liver Transplantation

Critical updates in the 7th edition of the American Society for Apheresis guidelines

In vitro PUVA treatment triggers calreticulin exposition and HMGB1 release by dying T lymphocytes in GVHD: New insights in extracorporeal photopheresis

Contact Info

Product

Resources

About

Critical updates in the 7^th edition of the American Society for Apheresis guidelines